TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05827237

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical decision rule
Description: Clinical decision rule for acute chest pain, consisting of the Marburg Heart Score (5 questions) combined with a high-sensitive troponin I point of care test
Study: NCT05917145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSD0628
Description: A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSD0628
Description: A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSD0628
Description: A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
Study: NCT06410404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: A local anesthetic that will be instilled in the transversus thoracic plane in a dose of 15 ml of a 25% concentration on both sides of the sternum in both groups
Study: NCT06570629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oronasal CPAP
Description: In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal CPAP plus Chinstrap
Description: In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
Study: NCT06302062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: A one-day intravenous injection of cyclophosphamide was administered two days prior to the initial cell transfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: A one-day intravenous injection of cyclophosphamide was administered two days prior to the initial cell transfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: The IL-2 treatment will be continued for 5 days.
Study: NCT04737265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Guided Intervention
Description: NTproBNP above the upper limit of normal will trigger the initiation of heart failure therapy with counseling from a study investigator based on protocol specified algorithm.
Study: NCT06302062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: The IL-2 treatment will be continued for 5 days.
Study: NCT06126705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation: 18F-FDG
Description: Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
Study: NCT06302062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab Injection
Description: In group B, Serplulimab Injection was injected before and after cell transfusion. If two cell transfusions were performed,Serplulimab Injection were given again .
Study: NCT05407220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-1
Description: take it once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-3
Description: take it once per period
Study: NCT06382142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Administration by intravenous bolus for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral administration for a cycle of 3 weeks.
Study: NCT05180240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CardiolRx
Description: Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CardiolRx
Description: Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.
Study: NCT04486638

Intervention type: BIOLOGICAL
Intervention: Dengue Tetravalent Vaccine, Live
Description: Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous
Study: NCT06174259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent fasting
Description: 16/8 intermittent fasting (limiting foods and calorie-containing beverages to a set window of 8 hours per day)
Study: NCT06455839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Resipiration Mindfulness Therapy (GRMT)
Description: GRMT provides training in respiratory regulation, mindfulness and relaxation. The GRMT training will begin with a 15-minute introduction to the treatment model, followed by an hour of therapist-guided respiration (i.e., continuous rhythmic expansion of the chest, and relaxed exhalation involving release of all respiratory and peripheral musculature). The final 45 minutes will be used to discuss participant experiences during the GRMT training. GRMT training sessions will occur in-person and in a small group format (\<5 participants each).
Study: NCT05588271

Intervention type: OTHER
Intervention: Exposures
Description: This study is an observational study.Exposure factors is patients with pressure injury.
Study: NCT04684290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Septal Ablation
Description: Participants will be treated with alcohol septal ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Septal Myectomy
Description: Participants will be treated with surgical septal myectomy.
Study: NCT05068310

Intervention type: DEVICE
Intervention: Cellular resolution full-field optical coherence tomography
Description: Device: ApolloVue® S100 Image System

Intervention type: DEVICE
Intervention: Confocal microscopy
Description: Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
Study: NCT06491979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fatty acid mixture
Description: Fatty acid mixture (mainly saturated fatty acid, Omega-6, Omega-7, Omega-9), 83 milligrams per kilogram (of body weight) per day, for three weeks
Study: NCT06176885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Combination therapy with Camrelizumab monoclonal antibody will be administered after the initial two cycles of induction therapy.
Study: NCT05390580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagal nerve stimulation
Description: Stimulus of the auricular branch of the vagal nerve with the transcutaneous auricular vagal nerve stimulation.
Study: NCT05068310

Intervention type: DEVICE
Intervention: Optical coherence tomography imaging
Description: Device: Vivosight® will be used for skin imaging for a subset of skin lesions.

Intervention type: DEVICE
Intervention: Dermoscopy imaging
Description: Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
Study: NCT05370209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otinova® Ear Spray
Description: Ear spray
Study: NCT05681078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Matter of Balance: Managing Concerns about Falls
Description: A Matter of Balance is an evidence-based program targeting physical activity and fall prevention for adults 60 years of age and older. This program incorporates active learning discussions and activities along with exercise training to reduce the fear of falling, improve fall efficacy and management, and increase physical activity levels in older adults.
Study: NCT06494644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793
Description: Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793+ Itraconazole
Description: Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
Study: NCT05074303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: All subjects will receive the influenza vaccine.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza Vaccine
Description: All subjects will receive the influenza vaccine.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucan
Description: 2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 - 250 mg capsules/day of cellulose
Study: NCT06168448

Intervention type: OTHER
Intervention: Oral and written information
Description: Legal oral and written information given by physicians concerning additional examinations

Intervention type: OTHER
Intervention: Oral and written information
Description: Legal oral and written information given by physicians concerning additional examinations

Intervention type: OTHER
Intervention: Video information
Description: Explanatory video applied after physician's formal information
Study: NCT05134883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMR
Description: For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
Study: NCT06519747

Intervention type: DEVICE
Intervention: Cardiac monitoring device
Description: Portable, up to 14 days of monitoring
Study: NCT05390580

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous vagal nerve stimulation
Description: Patients assigned to the controls arm will have no electricity applied to the Auricular Branch of the Vagus Nerve. Stimulus will be provided to the lobule of the ear, which is not innervated by the Auricular Branch of the Vagus Nerve.
Study: NCT05780047

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mail-in Urine Test for EDCs
Description: Million Marker provides a mail-in urine test for Bisphenol A (BPA) and phthalates. Users take a comprehensive exposure survey (via the MM app), send back their samples, view their personalized reports with tailored product recommendations, make changes to reduce their exposures, and retest to monitor their progress. Participants will also fill out surveys to assess changes in their environmental health literacy, readiness to change, and analyses of lifestyle behaviors and product use.
Study: NCT04739423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clenbuterol (CST-103), nadolol (CST-107), matching placebo
Description: clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules
Study: NCT05307562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval training + analytical strength
Description: Patients will receive a training program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training + analytical strength and IMT
Description: Patients will receive a training program + IMT
Study: NCT04499482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Soy-fiber containing food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Soy-fiber containing food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Soy-fiber containing food
Study: NCT04305730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of a pedometer following surgery
Description: Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
Study: NCT01495715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06096350

Intervention type: DEVICE
Intervention: robotic assisted intervention
Description: Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.

Intervention type: DIAGNOSTIC_TEST
Intervention: hematochemical analysis
Description: Blood samples of patients will be collected from patients in the early morning (7:30-9:00 a.m.) after an overnight fast at T0 and at T1. Sera samples will be separated by centrifugation (3,000 rpm, 10 min, and 4 °C), divided into 0.5 mL aliquots, and rapidly stored at -80 °C. Subjects' and reference samples were thawed just before the diagnostic test.

Intervention type: DEVICE
Intervention: BIA, hand grip
Description: bioimpedentiometric analyses of muscular mass (T0 and T1), muscular force with hand grip

Intervention type: DIAGNOSTIC_TEST
Intervention: nutritional assessment, MNA,
Description: nutritional status assessment will be performed by: body mass index measurements, (height and weight measurements at T0 and at T1); a Mini Nutritional Assessment survey will be administered to patients at admission; a food questionnaire will be administered to patients during from T0 to T1.

Intervention type: DIAGNOSTIC_TEST
Intervention: stool sampling
Description: stool will be collected at T0 and at T1

Intervention type: DIAGNOSTIC_TEST
Intervention: urine sampling
Description: the first morning urine will be collected at T0 and at T1
Study: NCT06047587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-TrAC
Description: Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each.

Intervention type: OTHER
Group type: OTHER
Intervention: Care as Usual
Description: Care as usual as provided in prison.
Study: NCT05902975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiber reinforced composite resin space maintainer
Description: Bonding of fiber reinforced with composite resin on primary second molar and primary canine under rubber dam isolation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiber reinforced composite resin space maintainer
Description: Bonding of fiber reinforced with composite resin on primary second molar and primary canine under rubber dam isolation
Study: NCT05305638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.
Study: NCT05163990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous acupoint electrical stimulation
Description: The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
Study: NCT05032352

Intervention type: DRUG
Intervention: Adjuvant
Description: Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.

Intervention type: OTHER
Intervention: Observation
Description: All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.

Intervention type: OTHER
Intervention: Observation
Description: All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
Study: NCT06010563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve implantation (TPVI)
Description: A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenusP-ValveTM System
Description: VenusP-ValveTM System consists of two components:~1. Transcatheter Pulmonary Valve (TPV)~2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper.
Study: NCT06437366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Led Heart Math Training Program
Description: he nurse-led HeartMath training program consists of several key components designed to enhance resilience, sense of coherence, and emotional adjustment:~Heart-Focused Breathing Techniques: Patients are taught specific breathing techniques that help synchronize heart and brain activity, leading to a state of physiological coherence.~Emotional Regulation Skills: The training includes exercises that help individuals recognize and shift from negative to positive emotional states, thereby improving emotional stability and reducing stress.
Study: NCT05444439

Intervention type: GENETIC
Group type: OTHER
Intervention: detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent H.Pylori genotypes by polymerase chain reaction amplification(PCR) in gastric biopsies :
Description: Extraction of DNA, using Wizard® Genomic DNA Purification Kit (Promega-USA), will be done following the manufacturer instructions. For detection of vacuolating cytotoxin A and cytotoxin-associated gene A gene, polymerase chain reaction amplification will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 60˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. For detection of vacuolating cytotoxin A (S1/S2, m1, m2), PCR will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 56˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. Amplified DNA will be analyzed by agarose gel electrophoresis. A positive sample will give bands at DNA fragment 138-bp for cytotoxin-associated gene A, at 259/286-bp for vacuolating cytotoxin A s1/s2, and 290-bp and 352-bp for m1 \& m2, respectively

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Culture and sensitivity of endoscopic gastric biopsies:
Description: During endoscopy, three biopsies will be taken from antrum and/or corpus of and will be examined by rapid urease test also known as Campylobacter-like organism test (Kimberly-Clark,USA). Culture of the bacterium on Columbia agar plus 5-7% defibrinated horse or sheep blood and selective Dent supplement under microaerophilic condition at 37degree Celsius for 3-5days.